Detalhe da pesquisa
1.
C3-targeted host-modulation approaches to oral inflammatory conditions.
Semin Immunol
; 59: 101608, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691883
2.
Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.
Semin Immunol
; 60: 101640, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853795
3.
The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.
J Immunol
; 211(3): 453-461, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306457
4.
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.
Clin Immunol
; 215: 108450, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32360516
5.
Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Clin Immunol
; 214: 108391, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32229292
6.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Clin Immunol
; 220: 108598, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961333
7.
Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.
Semin Immunol
; 28(3): 285-91, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27021500
8.
Safety profile after prolonged C3 inhibition.
Clin Immunol
; 197: 96-106, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30217791
9.
Applying complement therapeutics to rare diseases.
Clin Immunol
; 161(2): 225-40, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26341313
10.
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Eur J Clin Invest
; 45(4): 423-40, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25678219
11.
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Sci Adv
; 8(33): eabo2341, 2022 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977025
12.
Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.
J Clin Invest
; 131(23)2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618684
13.
Author Correction: Complement as a target in COVID-19?
Nat Rev Immunol
; 20(7): 448, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32533108
14.
Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
Front Immunol
; 10: 406, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30915073
15.
Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Semin Hematol
; 55(3): 167-175, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032754
16.
Clinical, imaging and pathological correlates of a hereditary deficit in verb and action processing.
Brain
; 129(Pt 2): 321-32, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16330501
17.
Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates.
Mol Ther Methods Clin Dev
; 6: 207-215, 2017 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28879212
18.
From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
Immunobiology
; 221(10): 1046-57, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27353192
19.
Tau and alpha-synuclein inclusions in a case of familial frontotemporal dementia and progressive aphasia.
J Neuropathol Exp Neurol
; 64(3): 245-53, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15804056
20.
Association between tau H2 haplotype and age at onset in frontotemporal dementia.
Arch Neurol
; 62(9): 1419-22, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16157749